• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    3/7/24 12:31:22 PM ET
    $APM
    $BEAT
    $BYSI
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $APM alert in real time by email

    Gainers

    • Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 35.3% to $1.38 during Thursday's regular session. The market value of their outstanding shares is at $18.4 million.
    • ZyVersa Therapeutics (NASDAQ:ZVSA) stock increased by 28.74% to $0.99. The company's market cap stands at $4.5 million.
    • Creative Medical Tech (NASDAQ:CELZ) stock increased by 28.18% to $6.1. The market value of their outstanding shares is at $8.4 million.
    • HeartBeam (NASDAQ:BEAT) stock rose 26.53% to $2.05. The company's market cap stands at $53.9 million.
    • Ocean Biomedical (NASDAQ:OCEA) shares increased by 24.4% to $5.03. The market value of their outstanding shares is at $171.3 million.
    • Quantum-Si (NASDAQ:QSI) shares rose 22.36% to $1.97. The market value of their outstanding shares is at $279.2 million.

    Losers

    • Avid Bioservices (NASDAQ:CDMO) stock fell 31.2% to $6.04 during Thursday's regular session. The market value of their outstanding shares is at $382.2 million.
    • Aptorum Gr (NASDAQ:APM) stock fell 31.2% to $6.53. The company's market cap stands at $33.8 million.
    • Nexalin Technology (NASDAQ:NXL) shares fell 27.93% to $0.37. The market value of their outstanding shares is at $2.7 million.
    • BeyondSpring (NASDAQ:BYSI) stock declined by 20.18% to $2.73. The company's market cap stands at $106.5 million.
    • PepGen (NASDAQ:PEPG) stock decreased by 19.54% to $12.4. The market value of their outstanding shares is at $388.6 million. The company's, Q4 earnings came out yesterday.
    • Viking Therapeutics (NASDAQ:VKTX) shares declined by 19.46% to $73.44. The company's market cap stands at $7.9 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APM
    $BEAT
    $BYSI
    $CDMO

    CompanyDatePrice TargetRatingAnalyst
    Heartbeam Inc.
    $BEAT
    12/11/2025$8.00Speculative Buy → Buy
    The Benchmark Company
    Heartbeam Inc.
    $BEAT
    12/8/2025$2.50Buy
    H.C. Wainwright
    Heartbeam Inc.
    $BEAT
    10/31/2025$4.00Buy
    Roth Capital
    Viking Therapeutics Inc.
    $VKTX
    10/29/2025$106.00Buy
    Canaccord Genuity
    PepGen Inc.
    $PEPG
    9/9/2025$6.00Buy
    Guggenheim
    Viking Therapeutics Inc.
    $VKTX
    4/29/2025$104.00Overweight
    Cantor Fitzgerald
    Viking Therapeutics Inc.
    $VKTX
    4/8/2025$30.00Neutral
    Goldman
    Viking Therapeutics Inc.
    $VKTX
    2/13/2025$102.00Sector Outperform
    Scotiabank
    More analyst ratings

    $APM
    $BEAT
    $BYSI
    $CDMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HeartBeam upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded HeartBeam from Speculative Buy to Buy and set a new price target of $8.00

    12/11/25 8:45:10 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright initiated coverage on HeartBeam with a new price target

    H.C. Wainwright initiated coverage of HeartBeam with a rating of Buy and set a new price target of $2.50

    12/8/25 8:34:44 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Roth Capital initiated coverage on HeartBeam with a new price target

    Roth Capital initiated coverage of HeartBeam with a rating of Buy and set a new price target of $4.00

    10/31/25 8:19:51 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $APM
    $BEAT
    $BYSI
    $CDMO
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by PepGen Inc.

    SCHEDULE 13G - PepGen Inc. (0001835597) (Subject)

    3/11/26 4:06:24 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Aptorum Group Limited

    6-K - Aptorum Group Ltd (0001734005) (Filer)

    3/11/26 4:00:01 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Aptorum Group Limited

    6-K - Aptorum Group Ltd (0001734005) (Filer)

    3/6/26 4:30:58 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $BEAT
    $BYSI
    $CDMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Viking Therapeutics Inc.

    4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

    3/10/26 6:20:39 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dowdy Paula bought $104,450 worth of shares (109,890 units at $0.95), increasing direct ownership by 69% to 269,107 units (SEC Form 4)

    4 - Quantum-Si Inc (0001816431) (Issuer)

    3/9/26 6:01:13 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Director Kummeth Charles R. bought $459,800 worth of shares (500,000 units at $0.92), increasing direct ownership by 141% to 855,000 units (SEC Form 4)

    4 - Quantum-Si Inc (0001816431) (Issuer)

    3/9/26 6:01:59 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    $APM
    $BEAT
    $BYSI
    $CDMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dowdy Paula bought $104,450 worth of shares (109,890 units at $0.95), increasing direct ownership by 69% to 269,107 units (SEC Form 4)

    4 - Quantum-Si Inc (0001816431) (Issuer)

    3/9/26 6:01:13 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Director Kummeth Charles R. bought $459,800 worth of shares (500,000 units at $0.92), increasing direct ownership by 141% to 855,000 units (SEC Form 4)

    4 - Quantum-Si Inc (0001816431) (Issuer)

    3/9/26 6:01:59 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Former 10% Owner Oxford Science Enterprises Plc bought $640,000 worth of shares (200,000 units at $3.20), increasing direct ownership by 4% to 4,955,388 units (SEC Form 4)

    4 - PepGen Inc. (0001835597) (Issuer)

    10/1/25 1:07:57 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $BEAT
    $BYSI
    $CDMO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today reinforced how its strategic investment in PsyLabs strengthens its control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure – a critical differentiator in the rapidly expanding psychedelic pharmaceutical sector. Through its investment in PsyLabs, Psyence BioMed has secured: A licensed, owned, and debt-free production operation.Source-level ibogaine supply.Natural psilocybin supply.GMP-compliant manufacturing capabilities.Intellectual property protection.Integrated analytical and chemistry laboratory infrastructure.A capital structur

    3/11/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania

    NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the publication of a paper by Giliberto, et. al. titled "Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens" in Diagnostics, (https://doi.org/10.3390/diagnostics16050791), a leading peer-reviewed journal focused on clinical diagnostics and biomarker research. This study, condu

    3/10/26 8:00:00 AM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HeartBeam and Mount Sinai Announce Strategic AI Collaboration to Bring Clinical-Grade Heart Monitoring into the Home

    Accelerates development of personalized cardiac AI on the HeartBeam platform for wellness and clinical applications, including assessing heart attack risk Combines Mount Sinai's world-class AI and clinical expertise with HeartBeam's groundbreaking 3D ECG signal collection technology HeartBeam is the only platform capable of collecting 12-lead ECG data from patients anytime, anywhere, over time – extending access beyond traditional clinical settings Positions HeartBeam to expand from symptom-based cardiac rhythm monitoring into AI-enabled disease assessment and management HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providin

    3/10/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $APM
    $BEAT
    $BYSI
    $CDMO
    Leadership Updates

    Live Leadership Updates

    View All

    Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today reinforced how its strategic investment in PsyLabs strengthens its control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure – a critical differentiator in the rapidly expanding psychedelic pharmaceutical sector. Through its investment in PsyLabs, Psyence BioMed has secured: A licensed, owned, and debt-free production operation.Source-level ibogaine supply.Natural psilocybin supply.GMP-compliant manufacturing capabilities.Intellectual property protection.Integrated analytical and chemistry laboratory infrastructure.A capital structur

    3/11/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

    NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the "Meeting"), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the "Board"). All director nominees listed in the Company's management informat

    2/17/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer

    Brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies Will initially focus on launching the Company's FDA-cleared 12-lead ECG system for arrhythmia assessment Will lead the Company's broader commercialization strategy across key growth initiatives, including heart attack detection and the 12-lead ECG extended-wear patch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strate

    1/22/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $APM
    $BEAT
    $BYSI
    $CDMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avid Bioservices Inc.

    SC 13G - Avid Bioservices, Inc. (0000704562) (Subject)

    12/13/24 10:53:25 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Psyence Biomedical Ltd.

    SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/13/24 9:16:01 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/9/24 1:36:43 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $BEAT
    $BYSI
    $CDMO
    Financials

    Live finance-specific insights

    View All

    HeartBeam to Host Fourth Quarter Full Year 2025 Results Conference Call on Thursday, March 12, 2026 at 4:30 p.m. Eastern Time

    HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, March 12, 2026 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2025, and will be providing updates on its key strategic growth initiatives, specifically the limited commercial launch and significant developments on the 12-lead ECG extended wear patch. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. They will

    3/4/26 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Quantum-Si Reports Fourth Quarter and Full Year 2025 Financial Results

    Releases List Price of Proteus™ Platform Reiterates Proteus Development Program On Track for Year End 2026 Launch Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced financial results for the fourth quarter and full year ended December 31, 2025. Press Release Highlights Reported fourth quarter revenue of $451,000 Reported on track development of the Proteus platform and related R&D programs to expand proteome coverage and enable broad PTM analysis capabilities Announced list price for Proteus of $425,000 Announced 2026 Financial Guidance

    3/3/26 4:05:00 PM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

    Conference call scheduled for 4:30 p.m. ET today Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full EnrollmentVK2735 Maintenance Dosing Study Fully Enrolled; Data Expected 3Q26Novel Amylin Agonist IND Filing Planned This Quarter Strong Quarter-End Cash Position of $706 MillionSAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended

    2/11/26 4:16:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care